GBCS · Selectis Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.44M | $39.49M | $36.78M | $40.60M | $29.29M | $20.93M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $8.89M | $9.25M | $9.97M | $7.87M | $5.91M | $2.09M |
| Total Operating Expenses | $43.01M | $42.22M | $45.74M | $40.89M | $30.02M | $17.55M |
| D&A | $1.47M | $1.57M | $1.67M | $1.73M | $1.73M | $1.58M |
| Operating Income | ($1.56M) | ($2.73M) | ($8.96M) | ($286.6K) | ($729.0K) | $3.37M |
| Interest Expense | $1.73M | $2.05M | $2.17M | $2.23M | $2.50M | $2.14M |
| Income Tax | $800 | - | - | - | - | - |
| Net Income | ($1.02M) | ($2.42M) | ($3.97M) | ($2.40M) | ($2.25M) | $2.96M |
| EPS - Basic | ($0.34) | ($0.80) | ($1.31) | ($0.79) | ($0.82) | $1.10 |
| EPS - Diluted | ($0.34) | ($0.80) | ($1.31) | ($0.79) | ($0.82) | $1.10 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01M | $680.3K | $1.48M | $1.42M | $3.94M | $3.57M |
| Accounts Receivable | $2.28M | $2.62M | $2.09M | $2.90M | $3.51M | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $7.58M | $3.53M | $4.96M | $4.96M | $7.97M | - |
| Total Assets | $32.58M | $33.45M | $40.67M | $42.49M | $46.92M | $45.93M |
| Current Liabilities | $25.27M | $19.63M | $18.15M | $6.85M | $11.79M | - |
| Long-term Debt | $13.41M | $19.13M | $25.18M | $34.40M | $31.05M | $39.25M |
| Total Liabilities | $38.79M | $38.86M | $43.64M | $41.54M | $43.82M | $42.72M |
| Stockholders' Equity | ($6.21M) | ($5.41M) | ($2.96M) | $952.8K | $3.10M | $3.41M |
| Retained Earnings | ($21.24M) | ($20.19M) | ($17.75M) | ($13.74M) | ($11.32M) | ($9.04M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.88M | ($1.82M) | $536.7K | ($305.1K) | ($270.9K) | $2.73M |
| Investing Cash Flow | ($443.6K) | $2.45M | ($29.8K) | ($222.4K) | ($519.6K) | ($1.57M) |
| Financing Cash Flow | ($976.7K) | ($1.54M) | ($618.7K) | ($1.85M) | $1.61M | $1.82M |
| CapEx | $443.6K | $36.1K | $29.8K | $222.4K | $519.6K | $985.7K |
| Free Cash Flow | $1.44M | ($1.86M) | $506.9K | ($527.5K) | ($790.5K) | $1.75M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -3.8% | -6.9% | -24.4% | -0.7% | -2.5% | 16.1% |
| EBITDA margin | -0.2% | -2.9% | -19.8% | 3.6% | 3.4% | 23.7% |
| Net margin | -2.5% | -6.1% | -10.8% | -5.9% | -7.7% | 14.1% |
| Free cash flow margin | 3.5% | -4.7% | 1.4% | -1.3% | -2.7% | 8.4% |
| FCF / Net income | -1.42 | 0.77 | -0.13 | 0.22 | 0.35 | 0.59 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 21.5% | 23.4% | 27.1% | 19.4% | 20.2% | 10.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -3.1% | -7.2% | -9.8% | -5.6% | -4.8% | 6.4% |
| Return on equity | 16.4% | 44.8% | 134.0% | -251.4% | -72.6% | 86.6% |
| Return on invested capital | -17.2% | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.30 | 0.18 | 0.27 | 0.72 | 0.68 | - |
| Quick ratio | 0.30 | 0.18 | 0.27 | 0.72 | 0.68 | - |
| Cash ratio | 0.04 | 0.03 | 0.08 | 0.21 | 0.33 | - |
| Leverage | ||||||
| Debt / Equity | -2.16 | -3.54 | -8.49 | 36.10 | 10.01 | 11.50 |
| Debt / Assets | 0.41 | 0.57 | 0.62 | 0.81 | 0.66 | 0.85 |
| Debt / EBITDA | - | - | - | 23.78 | 30.92 | 7.92 |
| Interest coverage | -0.9x | -1.3x | -4.1x | -0.1x | -0.3x | 1.6x |
| Equity multiplier | -5.25 | -6.18 | -13.72 | 44.59 | 15.13 | 13.45 |
| Liabilities / Assets | 1.19 | 1.16 | 1.07 | 0.98 | 0.93 | 0.93 |
| Efficiency | ||||||
| Asset turnover | 1.27 | 1.18 | 0.90 | 0.96 | 0.62 | 0.46 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 20d | 24d | 21d | 26d | 44d | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | 4.8x |
| P / B | - | - | - | 15.2x | 6.2x | 42.9x |
| P / S | 0.2x | 0.1x | 0.4x | 0.4x | 0.7x | 7.0x |
| EV / EBITDA | - | - | - | 32.8x | 46.3x | 36.8x |
| Growth | ||||||
| Revenue growth (YoY) | 4.9% | 7.4% | -9.4% | 38.6% | 39.9% | 477.6% |
| Revenue CAGR (3y) | 0.7% | 10.5% | 20.7% | 123.8% | 110.7% | - |
| Revenue CAGR (5y) | 14.6% | 61.2% | 63.7% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 42.7% | 69.5% | -3026.8% | 60.7% | - | 159.5% |
| Net income growth (YoY) | 58.1% | 39.0% | -65.7% | -6.4% | - | - |
| EPS growth (YoY) | 57.5% | 38.9% | -65.8% | 3.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 33.3% | - | 1554.8% |
| FCF CAGR (5y) | -3.8% | - | - | - | - | - |
| Book value growth (YoY) | -14.8% | -82.5% | - | -69.3% | -9.1% | 497.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$41.44M totalHealth Care$41.38M · 99.8%
Management Fee Revenue$65.8K · 0.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.11
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Real Estate Investment Trusts
Comparing SELECTIS HEALTH against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jul 20, 2015 | $0.1000 |
| Jul 8, 2015 | $0.1000 |
| Apr 8, 2015 | $0.1000 |
| Dec 4, 2014 | $0.1000 |
| Apr 28, 2014 | $0.1000 |